

CLINIGEN FACTSHEET

WHAT IS OUR INVESTMENT CASE?

In becoming the trusted global leader in access to medicines, the Group has consistently delivered healthy financial performances and returns. Below are the reasons to invest in Clinigen.

UNIQUE COMBINATION OF BUSINESSES		GLOBAL CAPABILITY	
EXPERIENCED TEAM MANAGEMENT		MARKET-LEADING POSITIONS	
UNPARALLELED KNOWLEDGE AND EXPERTISE		SIGNIFICANT LONG-TERM GROWTH POTENTIAL	
HIGHLY CASH GENERATIVE		TRUSTED ETHICAL SUPPLIER	

WHAT ARE OUR STRATEGIC OBJECTIVES?

Delivering the right medicine, to the right patient, at the right time.

1 DEVELOP AND RETAIN TALENTED PEOPLE	2 UPGRADE TECHNOLOGY PLATFORM TO DRIVE ORGANIC GROWTH
3 EXPAND AND EMBED A GLOBAL COMMUNITY OF CUSTOMERS AND OPINION LEADERS	4 EXPAND PORTFOLIO OF ACQUIRED, GLOBAL AND REGIONAL ASSETS
5 BECOME THE 'GO TO' LEADER IN ETHICAL ACCESS TO UNLICENSED MEDICINES	6 EXTEND GLOBAL FOOTPRINT INTO REMAINING KEY MARKETS

FINANCIAL PERFORMANCE

ADJUSTED GROSS PROFIT (£M)

140.1  14%

ADJUSTED EBITDA (£M)

76.0  17%

ADJUSTED BASIC EARNINGS PER SHARE (PENNY)

45.4  10%

GLOBAL REACH AND LOCAL KNOWLEDGE

The Group has a complementary portfolio of businesses operating globally, enhancing our ability to provide access to medicines worldwide.



CLINIGEN
GROUP PLC

Financial information for the period ended 30 June 2018

OUR OPERATIONS

OF GROUP GROSS PROFIT

10%

CLINICAL TRIAL SERVICES

CTS is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials ('IITs').

OF GROUP GROSS PROFIT

44%

UNLICENSED MEDICINES

Clinigen is the global market-leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides 'on-demand' access globally to medicines which remain unlicensed at the point of care.

OF GROUP GROSS PROFIT

46%

COMMERCIAL MEDICINES

The Group acquires global rights to niche hospital-only and critical care products, revitalising these assets around the world and returning them back to sustained growth. The Group also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.